Using advanced imaging techniques to improve brain cancer diagnosis
Use of CEST (Chemical Exchange Saturation Transfer) Imaging in PET/MRI
NA · Centre Paul Strauss · NCT05464992
This study is testing a new imaging technique to see if adding special scans can help doctors better diagnose brain cancer in patients getting PET/MRI exams.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Paul Strauss (other) |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT05464992 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the diagnostic capabilities of PET/MRI scans by incorporating Chemical Exchange Saturation Transfer (CEST) imaging. CEST imaging allows for the detection of various metabolites in brain tissues, providing valuable biochemical information that can aid in the evaluation of gliomas and brain metastases. By adding CEST sequences to standard imaging protocols, the study seeks to improve sensitivity and spatial resolution in identifying pathological conditions. Patients undergoing PET/MRI exams for preoperative evaluation or recurrence assessment will be included in this innovative approach.
Who should consider this trial
Good fit: Ideal candidates include patients scheduled for PET/MRI exams due to glioma or brain metastases.
Not a fit: Patients with contraindications to MRI or those unable to provide consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and better treatment planning for patients with brain tumors.
How similar studies have performed: While CEST imaging is a relatively novel approach, preliminary studies have shown promise in enhancing imaging capabilities for various conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients admitted to the Nuclear Medicine and Molecular Imaging department of ICANS (Institut de cancérologie strasbourg Europe) for a PET/MRI exam dedicated to: * Preoperative evaluation of a cerebral expansion lesion * Evaluation of glioma recurrences * Evaluation of brain metastases * Evaluation of recurrence of metastases Exclusion Criteria: * Contraindication to the realization of an MRI * Minor or patients placed under guardianship or supervision * Patients deprived of liberty * Patients placed under judicial protection * Patients that are not able to express their consent * Pregnant and breastfeeding women
Where this trial is running
Strasbourg
- France Institut de cancérologie Strasbourg Europe — Strasbourg, France (RECRUITING)
Study contacts
- Study coordinator: Manon VOEGELIN
- Email: promotion-rc@icans.eu
- Phone: (0)368339523
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glioma, Brain Metastases